Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534432 | 0.95 | NR5A1 (0.54) | NR5A1SLC2A1LTA4HTP53TSHR | |
| SCHEMBL13303555 | 0.94 | SLC2A1 (0.53) | NR5A1SLC2A1LTA4HNPC1RAB9A | |
| SCHEMBL13033909 | 0.93 | NR5A1 (0.53) | NR5A1SLC2A1LTA4HTP53TSHR | |
| SCHEMBL13172437 | 0.85 | NR5A1 (0.63) | NR5A1SLC2A1LTA4HTP53TSHR | |
| SCHEMBL10943900 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA | |
| SCHEMBL5473083 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA | |
| SCHEMBL1573968 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA | |
| SCHEMBL2829024 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA | |
| SCHEMBL28373061 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA | |
| SCHEMBL11095674 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670121-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160060198-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, DNPEP, QPCTL | NR5A1 2883/4885SLC2A1 4330/4885LTA4H 763/4885 |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | NR5A1 3226/4885SLC2A1 3858/4885LTA4H 754/4885 |
| US-20160060198-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | NR5A1 3226/4885SLC2A1 3858/4885LTA4H 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.